Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Backed by 8VC.
About the role
The incumbent is responsible for formulating an integrated vision and strategy for communicating effectively with the investor community resulting in positive brand recognition and strong investor interest in Lyell. The Director or Senior Director, Investor Relations and Communications ensures that the Company’s scientific and clinical development strategy and progress are clearly communicated to investors, analysts, media, and the broad financial community. Found on 1752vc Careers, the job board for startup and VC roles.
What they're looking for
- Cross-functional experience leading through complexity, with the ability to influence and Strong executive presence with the ability to lead executive discussions, focus on detail
- Collaborative leadership style
- Track record of prioritizing and executing competing priorities in a fast-moving
- Willingness to “roll-up your sleeves” managing a diverse set of objectives, shifting fluidly
- Agile and creative thinker in external communications, uses sound judgement
More about this role
Using living cells to treat – and sometimes even cure – cancer is one of the most dramatic advances in modern medicine. Patients with hematologic malignancies have been successfully treated with cell therapies. However, these profound results have not yet been achieved in patients with solid tumors, representing approximately 90% of all cancers. And for patients with hematologic malignancies, there is a need for next-generation cell therapies that can deliver increased response rates and longer duration of response. We are a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies. Lyell’s product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical response. We were founded by cell therapy pioneers whose decades of research elevated the broader understanding of T-cell biology and its interaction with cancer. In our quest to advance next-generation CAR T-cell therapies, we have built a fully integrated company capable of...
Browse similar: Startup jobs